Discovery of Small Molecule Therapeutics for Treatment of Chronic HBV Infection

Area of Science:

• Hepatology
• Virology
• Drug Discovery

Background:

• Chronic hepatitis B virus (HBV) infection impacts 250 million people worldwide, posing a significant public health challenge.
• A substantial number of patients with chronic hepatitis B (CHB) progress to cirrhosis and hepatocellular carcinoma (HCC).
• Current standard therapies for CHB offer limited clinical cure rates, highlighting an unmet medical need.

Purpose of the Study:

• To review recent advancements in the discovery and development of novel anti-HBV small molecules.
• To explore the potential of combining molecules with distinct mechanisms of action (MoAs) for improved CHB treatment outcomes.
• To identify key components for future combination therapies aimed at achieving a functional cure for CHB.

Main Methods:

• Literature review of recent scientific publications and clinical trial data.
• Analysis of novel anti-HBV small molecules and their distinct mechanisms of action.
• Evaluation of combination therapy strategies for chronic hepatitis B.

Main Results:

• Multiple pharmaceutical companies and research institutions are actively developing new anti-HBV small molecules.
• Emerging small molecules show promise in targeting different stages of the HBV lifecycle.
• Combination of distinct MoA molecules is a promising strategy to enhance the functional cure rate.

Conclusions:

• Novel small molecules offer new hope for treating chronic hepatitis B.
• Combination therapy with distinct MoA molecules is likely essential for achieving a functional cure.
• Future research should focus on developing and testing these combination therapies for superior clinical efficacy.